Epothilone B enhances Class I HLA and HLA-A2 surface molecule expression in ovarian cancer cells.

摘要: Abstract Objective Ovarian cancer is the leading cause of death from gynecologic cancers in United States. Epothilone B (EpoB), Taxol and vinblastine are anti-neoplastic agents that interfere with microtubules arrest cell cycle G2/M phase. EpoB being evaluated phase III clinical trials, its analogs currently used treatment taxane-resistant metastatic breast cancer. Little known about effect these drugs on immune response to tumors. Cancer cells evade recognition by down-regulating HLA Class I expression, allowing escape surveillance destruction. Our data illustrates microtubule-interacting HLA-A2 expression as well modulation cytokine ovarian cells. Methods were treated different concentrations drugs. Cell surface mRNA transcription molecules was examined. IFNα, IL1β, IL12 IL6 also upon treatment. Results Low-dose EpoB, greatly increased Hey does not modulate drug-resistant The markedly Conclusions Nanomolar enhance immune-visibility increasing pro-inflammatory expression. Immune tumor may be improved.